Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

J&J Recalls 7,500 Hip Implants

February 14, 2013 1:49 pm | News | Comments

Johnson & Johnson has again recalled thousands of its hip implants, 2 1/2 years after the problem-plagued health care giant issued a recall of two other types of its artificial hips. J&J said it's recalled all 7,500 Adept implants shipped worldwide between 2004 and September 2011.

TOPICS:

Tracking Human Metabolism with Carbon-14

February 14, 2013 1:39 pm | by Sean L. Kitson, PhD, Investigator of Radiochemistry, Department of Biocatalysis and Radiolabeling; Almac; Craigavon, U.K. | Articles | Comments

A drug entering the body undergoes a series of biotransformations via phase I and phase II metabolic pathways. The metabolites produced have a similar chemical structure to the parent drug and are more pharmacologically active at the therapeutic receptor sites.

TOPICS:

Teva Gets Approval For Generic Adderall

February 14, 2013 12:17 pm | News | Comments

Teva Pharmaceutical Industries Ltd. said Thursday that it received marketing approval for a generic version of Shire PLC's Adderall XR, a treatment for attention deficit hyperactivity disorder. The Food and Drug Administration approved Teva's generic in six strengths from 5 milligrams to 30...

TOPICS:
Advertisement

eClinical Directions: Eliminating Technology Chaos

February 14, 2013 11:56 am | by Bill Byrom, PhD, Senior Director of Product Strategy; Perceptive Informatics, Nottingham, U.K. | Articles | Comments

There is a discernible cycle associated with the application of information technology: implementation, followed by an incremental gain, and then the surfacing of pain areas that need step changes to address them. The pharmaceutical industry is beginning a step-change that promises substantial operational value at site level, while extending application from individual studies to a corporate, strategic level.

TOPICS:

Dr. Reddy's Profit Sinks 26% in 3Q

February 14, 2013 11:11 am | News | Comments

Drugmaker Dr. Reddy's Laboratories Ltd. said Thursday its fiscal third-quarter earnings fell 26 percent compared to the same quarter last year, when a generic version of the antipsychotic Zyprexa boosted its North American sales. The Indian company reported net income of $69 million.

TOPICS:

Drug Delivery Using Cell-Penetrating Peptides

February 14, 2013 10:58 am | by Jyothi Thundimadathil, PhD, Technical Marketing Associate; American Peptide Company Inc., Sunnyvale, Calif. | Articles | Comments

The difficulty of delivering large molecules—proteins, peptides, and nucleic acids—into cells through the cell membrane (cellular uptake) has proven a significant impediment to medicinal chemists and the pharmaceutical industry as a whole.

TOPICS:

Merck Settles Cholesterol Suits for $688M

February 14, 2013 10:32 am | News | Comments

Merck & Co. has agreed to pay $688 million to settle two lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs, Vytorin and Zetia, to prevent a drop in sales.

TOPICS:

Switching Series

February 14, 2013 10:15 am | by Martin Slater, PhD, Director of Consulting; Katriona Scoffin, BSc, Science Writer; Cresset Group Ltd., Welwyn Garden City, U.K. | Articles | Comments

When researchers find their promising lead series facing IP issues, they are faced with a tough decision. Do they change series—possibly to a candidate that doesn’t show the same level of activity against the target—or do they spend a great deal of time and money screening for a new prospect?

TOPICS:
Advertisement

Cancer Treatment May Increase Leukemia Risk

February 14, 2013 10:01 am | News | Comments

A study has described the pattern of risk for one form of cancer, acute myeloid leukemia (AML), that has risen over the past three decades for adults who have previously been treated with chemotherapy for other forms of cancer, notably non-Hodgkin’s lymphoma.

TOPICS:

Automating High-Throughput Screening

February 14, 2013 9:54 am | by Mike May, Contributing Editor | Articles | Comments

To automate today’s high-throughout screening, researchers need a combination of hardware and software. As always, robotic arms and liquid-handling systems bring improvements to these processes, but keeping such complicated workflows efficient requires software tools that track the processes and samples.

TOPICS:

Mylan to Develop Biocon Generics

February 13, 2013 6:14 pm | News | Comments

Mylan Inc. said it will help market generic versions of some of the biggest-selling insulin drugs in the world under a new agreement with Biocon Ltd., India's largest biotechnology company by revenue. The companies did not disclose terms of the deal.

TOPICS:

Qiagen, Lilly Expand Diagnostic Partnership

February 13, 2013 5:34 pm | News | Comments

Diagnostic products maker Qiagen NV will work with Eli Lilly to develop new tests that could identify patients who could be helped by Lilly's drugs. The companies did not disclose terms of the new collaboration, but described it as a "broad" partnership that will cover "all therapeutic areas."

TOPICS:

J&J Loses $109M Lawsuit

February 13, 2013 4:04 pm | News | Comments

A Plymouth Superior Court jury decided Johnson & Johnson and its McNeil Laboratories subsidiary should pay Samantha Reckis and her parents a total of $109 million, including interest, after she suffered a life-threatening drug reaction and lost most of her skin when she took a children's pain reliever nearly a decade ago.

TOPICS:

Trial Indicates Cancer Survival Improvement

February 13, 2013 4:02 pm | News | Comments

Peregrine Pharmaceuticals' Phase 2 clinical trial of bavituximab, used in combination with gemcitabine. Results showed that the combination resulted in more than a doubling of overall response rates (ORR) and an improvement in overall survival (OS) when compared with gemcitabine alone (control arm).

TOPICS:

RQx, Genentech Enter $111M 'Novel' Drug Collaboration

February 13, 2013 2:34 pm | News | Comments

RQx Pharmaceuticals announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group, for the discovery and development of novel drug compounds for an undisclosed target.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading